Tag: relapsed/refractory
ADC Therapeutics On Track to File BLA for Loncastuximab Tesirine for...
This week Swiss-based ADC Therapeutics, a late clinical-stage oncology-focused biotechnology company pioneering the development of antibody-drug conjugates (ADCs) for patients with hematological malignancies and...
First Patients Dosed with Combination of Loncastuximab Tesirine + Ibrutinib in...
Diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) are two distinct subtypes of non-Hodgkin lymphoma (NHL). These hematological malignancies are associated with...
